Involvement of the transforming growth factor β in the pathogenesis of hereditary hemorrhagic telangiectasia

被引:7
作者
Jirillo, E.
Amati, L.
Suppressa, P.
Cirimele, D.
Guastamacchia, E.
Covelli, V.
Tafaro, E.
Sabba, C.
机构
[1] Natl Inst Gastroenterol, Bari, Italy
[2] Univ Bari, Fac Med, Dept Internal Med & Publ Hlth, I-70121 Bari, Italy
[3] Univ Bari, Fac Med, Dept Emergency & Organ Transplantat, I-70121 Bari, Italy
[4] Azienda Osped Policlin, Div Neurol, Bari, Italy
[5] Univ Bari, Fac Med, Dept Applicat Surg Innovat Technol, I-70121 Bari, Italy
关键词
activin receptor-like kinase 1; angiogenesis; endoglin; hereditary hemorrhagic telangiectasia; immunity; transforming growth factor; tumorigenesis;
D O I
10.2174/138161206776361228
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Hereditary hemorrhagic telangiectasia (HHT) is characterized by vessel alterations such as dilatation of postcapillary venules and arterio-venous communications, which account for the major clinical manifestations of the disease. Two types of HHT have been characterized HHT-1 and HHT-2, respectively, depending the former on endoglin mutations and the latter on activin receptor-like kinase 1 (ALK-1) mutations. Both endoglin and ALK-1 bind to the transforming growth factor (TGF) superfamily which, physiologically, regulates the activities of endothelial cells and also those related to the extracellular matrix. In this review, the salient features of TGF-beta will be outlined with special reference to its activity on the immune system and on tumorigenesis. Furthermore, the involvement of TGF-beta in the pathogenesis of some gastrointestinal diseases will be discussed and, in particular, in the course of liver disease, Helicobacter pylori infection and inflammatory bowel disease. In the light of these data and of animal model of HHT, the potential risk of developing other diseases in HHT patients will be discussed.
引用
收藏
页码:1195 / 1200
页数:6
相关论文
共 104 条
[1]  
Akhurst RJ, 1999, J PATHOL, V187, P82, DOI 10.1002/(SICI)1096-9896(199901)187:1<82::AID-PATH248>3.0.CO
[2]  
2-8
[3]   Pathogenesis of liver fibrosis [J].
Alcolado, R ;
Arthur, MJP ;
Iredale, JP .
CLINICAL SCIENCE, 1997, 92 (02) :103-112
[4]  
Alexandrow MG, 1997, J CELL BIOCHEM, V66, P427, DOI 10.1002/(SICI)1097-4644(19970915)66:4<427::AID-JCB1>3.0.CO
[5]  
2-N
[6]  
Amati L, 1999, ITAL J GASTROENTEROL, V31, P313
[7]   Immune abnormalities and endotoxemia in patients with ulcerative colitis and in their first degree relatives: Attempts at neutralizing endotoxin-mediated effects [J].
Amati, L ;
Caradonna, L ;
Leandro, G ;
Magrone, T ;
Minenna, M ;
Faleo, G ;
Pellegrino, NM ;
Jirillo, E ;
Caccavo, D .
CURRENT PHARMACEUTICAL DESIGN, 2003, 9 (24) :1937-1945
[8]   Modifications of the immune responsiveness in patients with hepatitis C virus infection following treatment with IFN-α/Ribavirin [J].
Amati, L ;
Caradonna, L ;
Magrone, T ;
Mastronardi, ML ;
Cuppone, R ;
Cozzolongo, R ;
Manghisi, OG ;
Caccavo, D ;
Amoroso, A ;
Jirillo, E .
CURRENT PHARMACEUTICAL DESIGN, 2002, 8 (11) :981-993
[9]  
AMATI L, 2005, IMMUNOLOGICAL CONSEQ, V11
[10]  
AMATI L, 2004, DRUG DESIGN REV ON L, V2, P111